EN DE

Mytrex Health Technologies, Inc. (4431) Fair Value & Analysis

Industrials · TW · Market cap 669M TWD

MH Mytrex Health Technologies, Inc. 4431 · TWO
Price18.75 TWD
Fair Value21.18 TWD
Upside+13.0%
Quality68/100
Watch Mytrex Health Technologies, Inc. for free, get notified when fair value or trend changes. Watch for free

Strengths

Trades 11% below our fair value of 21.18 TWD
Low debt · generates free cash flow

Risks

!Mixed Growth (revenue 5y +13.7 %/yr)
!Loss-making · -0.9% net margin
!Mixed vs. peers (6/11)
!Narrow moat 16/100
Mixed Growth (revenue 5y +13.7 %/yr)
Loss-making · -0.9% net margin
Low debt · generates free cash flow
Mixed vs. peers (6/11)
Narrow moat 16/100
Evidence: Medium Range 16.21 TWD – 26.14 TWD Share as image

Fair value as of: Aug 13, 2026

From 13 valuation models · updated 11 days ago

Share price +5.6% over the past month.

A solid business, trading 11% below our fair value.

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Track Mytrex Health Technologies, Inc. and get told automatically when its fair value or trend turns, plus fair value for all 35,000+ stocks. 14 days of Pro free, no card.

What matters now

  • Our model range runs from 16.21 TWD (bear) to 26.14 TWD (bull), base 21.18 TWD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 68/100 (solid quality) with medium evidence: read the verdict with care.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

49.23 TWD 13.50 TWD Fair Value 21.18 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 13.50 TWD – 49.23 TWD · fair‑value band 16.21 TWD – 26.14 TWD · the 18.75 TWD price screens below the 21.18 TWD fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Mytrex Health Technologies, Inc. (4431) currently trades at 18.75 TWD, while our model-based Fair Value estimate is 21.18 TWD, implying the stock looks roughly 13.0% undervalued today. The Quality Score stands at 68/100 (solid quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Mytrex Health Technologies, Inc. generated revenue of 1.9B TWD at a net margin of -0.9%. Revenue grew 3.5% year over year. It earns a return on equity of -4.3%. The balance sheet holds a net cash position of 48.6M TWD. Fundamentals as of Aug 13, 2026

Our scenario range runs from 16.21 TWD (bear case) to 26.14 TWD (bull case); at 18.75 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 20% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at -51% fair-value upside, at 13%, 4431 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 76.17 TWD 125.67 TWD 203.45 TWD 80
Rev-Margin DCF 73.39 TWD 122.40 TWD 225.07 TWD 74
Gordon GGM 25.90 TWD 46.67 TWD 64.24 TWD 70
All 13 models by family
DCF Models
FCF DCF 80.76 TWD 114.11 TWD 213.77 TWD 38
Owner Earnings 26.12 TWD 45.31 TWD 80.93 TWD 31
5Y Revenue Exit 67.39 TWD 108.05 TWD 192.92 TWD 39
5Y EBITDA Exit 41.80 TWD 56.36 TWD 84.48 TWD 41
10Y Revenue Exit 70.37 TWD 137.25 TWD 177.77 TWD 36
10Y EBITDA Exit 55.13 TWD 86.99 TWD 134.64 TWD 37
Dividend Discount
Gordon GGM 25.90 TWD 46.67 TWD 64.24 TWD 70
DDM Multi-Stage 25.90 TWD 42.63 TWD 49.85 TWD 61
Multiples
EV/EBITDA 23.11 TWD 28.08 TWD 33.04 TWD 54
EV/Revenue 56.72 TWD 77.50 TWD 98.28 TWD 43
Asset-Based
NCAV (Graham) 8.00 TWD 10.73 TWD 16.01 TWD 50
Growth DCF
Growth DCF 76.17 TWD 125.67 TWD 203.45 TWD 80
Rev-Margin DCF 73.39 TWD 122.40 TWD 225.07 TWD 74

Widest divergence: Growth DCF (122.40 TWD) versus Asset-Based (10.73 TWD). Highest evidence: Growth DCF (80).

Notify me when 4431 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 0.31 TTM
Net margin -0.9% TTM
Return on equity -4.3% TTM
Return on assets -1.4% TTM
Operating margin -0.4% TTM
EPS (TTM) -0.4500 TWD
More key figures
Growth
Revenue (TTM) 1.9B TWD TTM
Revenue growth (YoY) +3.5% 3y avg +9.7%
Balance sheet & cash flow
Free cash flow 195M TWD FY2025
Net cash 48.6M TWD FY2024

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 69 · Market factors (momentum, volatility) 47

Profitability 33
Margins and returns on capital today
Quality Growth 71
Are margins and returns improving?
Cashflow 65
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 65
Calm price path (market factor)
Momentum 42
Price trend over the last 3–12 months (market factor)
52W Momentum 35
Distance to the 52-week high (market factor)
Net Issuance 83
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Mytrex Health Technologies, Inc. engages in the manufacturing, processing, and sale of various filter non-woven fabrics in Taiwan, rest of Asia, Europe, and internationally.

Full company description

Mytrex Health Technologies, Inc. engages in the manufacturing, processing, and sale of various filter non-woven fabrics in Taiwan, rest of Asia, Europe, and internationally. The company provides electrostatic filtration materials for medical and industrial mask media, and other filtration applications; and composite nonwoven products for coolant and air filter, vacuum filter bag, HEPA and cabin filter, and water filtration compound material applications. It also offers thermal insulation products for glove, sock, shoe, hat, clothing material, and mask insulation material applications; and linen laundry and leasing, logistic, and medical supplies for hospitals. In addition, the company sells pharmaceuticals and medical hygiene materials; and manages medical clothing products. Mytrex Health Technologies, Inc. was founded in 1990 and is based in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Mytrex Health Technologies, Inc. reported revenue of 1.9B TWD in FY2025 versus 292M TWD in FY2021, a compound +60.7%/yr. Reported net income was −16.6M TWD in FY2025.

Growth Quality 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
1.9B TWD
Latest YoY
+10.6%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+9.7%
Avg. revenue growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.7%
Avg. revenue growth/yr (6Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+30.2%
Value creation/yr We only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Revenue +60.7%/yr
FY21 292M TWD
FY22 1.5B TWD
FY23 1.3B TWD
FY24 1.8B TWD
FY25 1.9B TWD
Net income
FY21 −14.0M TWD
FY22 −91.9M TWD
FY23 −56.2M TWD
FY24 −82.4M TWD
FY25 −16.6M TWD

Watch 4431: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Mytrex Health Technologies, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/4431

Peer Group

Specialty Industrial Machinery · 819 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside +13% · Top 25%
Return on assets -1% · Bottom 25%
Net margin (TTM) -1% · Bottom 25%
Operating margin (TTM) -0% · Bottom 25%
Revenue growth 4% · Below median
Dividend yield (TTM) 20.0% · Top 25%

Valuation Multiples vs Specialty Industrial Machinery median · lower = cheaper

P/S (TTM) 0.01× · Cheaper than 75% of peers
P/FCF 0.1× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE51 · sector 0
FUTURE18 · sector 22
PAST0 · sector 28
HEALTH100 · sector 96
DIVIDEND100 · sector 27

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
GE Vernova Inc GEV $966.01 $131.95 -86%
SIE SIE €281.95 €139.77 -50%
Eaton Corporation ETN $459.96 $168.65 -63%
Parker-Hannifin Corporation PH $1,042 $398.69 -62%
Atlas Copco AB ATCOA kr 202.30 kr 112.59 -44%
Cummins Inc CMI $637.85 $348.94 -45%
Illinois Tool Works Inc ITW $292.51 $145.84 -50%
Emerson Electric Co EMR $163.80 $58.44 -64%
AMETEK, Inc AME $258.52 $125.80 -51%
Rockwell Automation, Inc ROK $451.39 $125.76 -72%

Compare Mytrex Health Technologies, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Mytrex Health Technologies, Inc. (4431) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 21.18 TWD versus a price of 18.75 TWD, about +13% (undervalued).
What is the fair value of 4431?
Our model-based fair value for Mytrex Health Technologies, Inc. is 21.18 TWD (as of Aug 13, 2026), built from audited fundamentals. The current price: 18.75 TWD.
What is the quality score of 4431?
Mytrex Health Technologies, Inc. has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Mytrex Health Technologies, Inc. (4431)?
Mytrex Health Technologies, Inc. reported trailing-twelve-month revenue of about 1.9B TWD (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 4431?
The net profit margin of Mytrex Health Technologies, Inc. is about -0.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Mytrex Health Technologies, Inc. and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.